US EditionZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm
- Rosen Law Firm filed a securities class action lawsuit concerning Zenas BioPharma, Inc.'s September 2024 IPO listed under NASDAQ: ZBIO.
- The suit alleges that Zenas BioPharma’s Registration Statement contained false and misleading statements about the duration its cash and IPO proceeds would fund operations.
- The lead plaintiff deadline to move the Court is June 16, 2025, and a lead plaintiff directs litigation on behalf of other investors who purchased ZBIO securities.
- Rosen Law Firm previously secured over $438 million in settlements and Laurence Rosen was named a Titan of Plaintiffs' Bar in 2020, indicating experience in similar cases.
- Individuals who purchased shares of Zenas BioPharma have the opportunity to seek compensation through a contingency fee agreement that requires no upfront costs, provided they take action before the June 16, 2025 deadline.
Insights by Ground AI
Does this summary seem wrong?
24 Articles
24 Articles
All
Left
4
Center
7
Right
3
ZBIO INVESTOR DEADLINE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO, May 27, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial…
·United States
Read Full ArticleCoverage Details
Total News Sources24
Leaning Left4Leaning Right3Center7Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 29%
C 50%
R 21%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
